PubMed · 147132
Acquired platelet dysfunction following mithramycin therapy.
Abstract
The administration of mithramycin to patients with testicular tumors has been accompanied by a hemorrhagic diasthesis, often in the absence of thrombocytopenia. Bleeding time, platelet aggregation, platelet adenine nucleotide levels, and coagulation factor assays were studied in three patients receiving mithramycin for embryonal testicular carcinomas. These studies demonstrated a drug dependent, reversible hemorrhagic diathesis associated with (1) prolongation of bleeding time, (2) decreased platelet aggregation responses to ADP, collagen, and epinephrine, and (3) depleted platelet stores of ADP in the absence of thrombocytopenia. These abnormalities were temporally correlated with the onset of mucocutaneous bleeding in all patients.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
D J Ahr, S J Scialla, D B Kimbali. 1978. Acquired platelet dysfunction following mithramycin therapy.. https://doi.org/10.1002/1097-0142(197802)41%3A2%3C448%3A%3Aaid-cncr2820410211%3E3.0.co%3B2-u
Cite the original work for its findings. Save a collection to share your selection of sources.